Clay Siegall: BioGenetics Visionary and Entrepreneur

// Published September 9, 2017 by User1

Clay Siegall is an entrepreneur and visionary in the field of biotechnology. He is the chief executive and cofounder of Seattle Genetics. The company is making inroads in cancer research by coming up with groundbreaking therapies that will help cancer patients.

Clay Siegall was interested in biology from a very young age. He finished college with B.Sc. in Zoology form the University of Maryland. He then went to George Washington University where he got a Doctor of Philosophy in Genetics. He founded Seattle Genetics in 1998 and he has been working in the Genetics field ever since. Siegall also serves on the boards of various biotechnology companies. He sits on Alder Biopharmaceutical’s board. Alder is a public company that is working on safe antibody therapeutics technology. He also serves as a director on the boards for Mirna Therapeutics and Ultragenyx Pharmaceutical. Before becoming an entrepreneur, Siegall worked at the National Cancer Institute and at Bristol-Myers Squibb as a researcher.

At Seattle Genetics Siegall has led the company as it tripled its stock price between 2011 and 2016. He was also a key player as Seattle Genetics developed the first antibody drug conjugate known as ADECTRIS. ADECTRIS is based on brentuximab vedotin and it is used to treat cancer patients in over 60 countries. The drug obtained FDA approval in late 2011. Many players in the industry praised Siegall for his role in the development of ADECTRIS and other antibody drug conjugates therapies. This type of drugs have achieved significant success in treating relapsed large cell lymphoma and Hodgkin lymphoma.

Clay Siegall also led the company when it listed on the NASDAQ exchange in 2001. The company has partnered with numerous big pharmaceutical companies to help it market the drug. In December 2009 the company partnered with GlaxoSmithKline in a deal that included a $12 million upfront payment and a further $390 million that will be paid as various milestones are reached. The company has other collaborations with Pfizer, Genetech, Bayer Celldex, Oxford BioTherapeutics, Daiichi Sankyo, AbbVie and PSMA Developments. Clay Siegall is leading the company as it explores advanced antibody conjugate treatments that use PBD cytotoxic agents and MMAE based conjugates.


Leave a Reply

Your email address will not be published. Required fields are marked *